Form 8-K Vanda Pharmaceuticals For: Jul 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/3/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
- Analysis-Excommunications show a Pope Leo unafraid of making firm decisions
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Canaccord Starts Infleqtion, Inc (INFQ) at Buy
- Jersey Mike's Subs files for IPO on NYSE under ticker JMKE
- AXT-Tongmei signs 3-year wafer supply deal with Coherent
Vanda Pharmaceuticals (VNDA) PT Raised to $13 at Cantor Fitzgerald
August 1, 2024 6:35 AM EDTCantor Fitzgerald analyst Charles Duncan raised the price target on Vanda Pharmaceuticals (NASDAQ: VNDA) to $13.00 (from $11.00) while maintaining a Overweight rating.
The analyst comments "Overall, we see VNDA as a differentiated Neuro-Innovator with a broadening neuropsych portfolio that should garner investors' interest as... More
